These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 27750483)

  • 1. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
    Seftel MD; Kuruvilla J; Kouroukis T; Banerji V; Fraser G; Crump M; Kumar R; Chalchal HI; Salim M; Laister RC; Crocker S; Gibson SB; Toguchi M; Lyons JF; Xu H; Powers J; Sederias J; Seymour L; Hay AE
    Leuk Lymphoma; 2017 Jun; 58(6):1358-1365. PubMed ID: 27750483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
    Song Y; Zhou K; Yang S; Hu J; Zou D; Gao S; Pan L; Wang T; Yang H; Zhang H; Zhou D; Ji J; Xu W; Feng R; Jin J; Lv F; Huang H; Fan X; Xu S; Zhu J
    Invest New Drugs; 2023 Aug; 41(4):606-616. PubMed ID: 37420136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
    Mato AR; Shah NN; Jurczak W; Cheah CY; Pagel JM; Woyach JA; Fakhri B; Eyre TA; Lamanna N; Patel MR; Alencar A; Lech-Maranda E; Wierda WG; Coombs CC; Gerson JN; Ghia P; Le Gouill S; Lewis DJ; Sundaram S; Cohen JB; Flinn IW; Tam CS; Barve MA; Kuss B; Taylor J; Abdel-Wahab O; Schuster SJ; Palomba ML; Lewis KL; Roeker LE; Davids MS; Tan XN; Fenske TS; Wallin J; Tsai DE; Ku NC; Zhu E; Chen J; Yin M; Nair B; Ebata K; Marella N; Brown JR; Wang M
    Lancet; 2021 Mar; 397(10277):892-901. PubMed ID: 33676628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
    Zent CS; Bowen DA; Conte MJ; LaPlant BR; Call TG
    Leuk Lymphoma; 2016 Jul; 57(7):1585-91. PubMed ID: 26699397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
    Fabre C; Gobbi M; Ezzili C; Zoubir M; Sablin MP; Small K; Im E; Shinwari N; Zhang D; Zhou H; Le Tourneau C
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1057-64. PubMed ID: 25217392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
    O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
    Izutsu K; Ando K; Ennishi D; Shibayama H; Suzumiya J; Yamamoto K; Ichikawa S; Kato K; Kumagai K; Patel P; Iizumi S; Hayashi N; Kawasumi H; Murayama K; Nagai H
    Cancer Sci; 2021 Jun; 112(6):2405-2415. PubMed ID: 33728735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell lymphoma resembling ultra-high risk chronic lymphocytic leukemia.
    Miao Y; Wang R; Fan L; Qiu H; Wu Y; Chen Y; Xu W; Li J
    Int J Clin Exp Pathol; 2015; 8(6):7494-8. PubMed ID: 26261659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
    Walter HS; Rule SA; Dyer MJ; Karlin L; Jones C; Cazin B; Quittet P; Shah N; Hutchinson CV; Honda H; Duffy K; Birkett J; Jamieson V; Courtenay-Luck N; Yoshizawa T; Sharpe J; Ohno T; Abe S; Nishimura A; Cartron G; Morschhauser F; Fegan C; Salles G
    Blood; 2016 Jan; 127(4):411-9. PubMed ID: 26542378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
    Weide R; Feiten S; Friesenhahn V; Heymanns J; Kleboth K; Thomalla J; van Roye C; Köppler H
    Leuk Lymphoma; 2013 Aug; 54(8):1640-6. PubMed ID: 23151046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study.
    Hoeller S; Zhou Y; Kanagal-Shamanna R; Xu-Monette ZY; Hoehn D; Bihl M; Swerdlow SH; Rosenwald A; Ott G; Said J; Dunphy CH; Bueso-Ramos CE; Lin P; Wang M; Miranda RN; Tzankov A; Medeiros LJ; Young KH
    Hum Pathol; 2013 Jan; 44(1):110-21. PubMed ID: 22944294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
    Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
    Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.
    Brown JR; Tesar B; Yu L; Werner L; Takebe N; Mikler E; Reynolds HM; Thompson C; Fisher DC; Neuberg D; Freedman AS
    Leuk Lymphoma; 2015; 56(12):3336-42. PubMed ID: 25971907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall.
    Qiu L; Xu J; Tang G; Wang SA; Lin P; Ok CY; Garces S; Yin CC; Khanlari M; Vega F; Medeiros LJ; Li S
    Hum Pathol; 2022 Jan; 119():59-68. PubMed ID: 34767860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
    Varma G; Johnson TP; Advani RH
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):543-54. PubMed ID: 27379948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
    Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
    Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and prognosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) and mantle cell lymphoma (MCL).
    Asaad NY; Abd El-Wahed MM; Dawoud MM
    J Egypt Natl Canc Inst; 2005 Dec; 17(4):279-90. PubMed ID: 17102815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
    Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
    J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.